12 Best Rising Penny Stocks To Buy
In this article, we will take a detailed look at the12 Best Rising Penny Stocks To Buy. For a quick overview of such stocks, read our article 5 Best Rising Penny Stocks To Buy. Stocks are roaring aft...
- Supported exchanges /
- NASDAQ /
- HRTX.NASDAQ
Heron Therapeuti (HRTX NASDAQ) stock market data APIs
$1.79
0.01(0.6%)
as of October 22, 2024
Price chart is built with Anychart
Heron Therapeutics, Inc., a commercial-stage biotechnology company, focuses on enhancing the lives of patients by developing and commercializing therapeutic that enhances medical care. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration. It offers SUSTOL (granisetron), an extended-release injection for the prevention of acute and delayed nausea and vomiting associated with moderately emetogenic chemotherapy, or anthracycline and cyclophosphamide combination chemotherapy regimens; and CINVANTI, an intravenous formulation of aprepitant, a substance P/neurokinin-1 receptor antagonist for the prevention of acute and delayed nausea and vomiting associated with highly emetogenic cancer chemotherapy, as well as nausea and vomiting associated with moderately emetogenic cancer chemotherapy. The company is also developing ZYNRELEF, a dual-acting local anesthetic that delivers a fixed-dose combination of the local anesthetic bupivacaine and a low dose of the nonsteroidal anti-inflammatory drug meloxicam; and APONVIE, an intravenous formulation of a substance P/neurokinin-1 receptor antagonist indicated for the prevention of postoperative nausea and vomiting in adults. The company was formerly known as A.P. Pharma, Inc. and changed its name to Heron Therapeutics, Inc. in January 2014. Heron Therapeutics, Inc. was founded in 1983 and is headquartered in San Diego, California.
Heron Therapeuti Financial Data Overview
| 1.78 | |
| 1.79 | |
| - | |
| 1.81 | |
| 1.7 | |
| 0.5-3.93 | |
| 270 M | |
| 152 M | |
| 136 M | |
| -0.06 | |
| 1.805 |
Our easy-to-use no-coding solutions help you get the data effortlessly:
No long-term obligations. The minimum period is one month only. No wait. You get an API key with instructions in a few seconds right after subscription.
General: {
Code:
'HRTX',
Type:
'Common Stock',
Name:
'Heron Therapeuti',
Exchange:
'NASDAQ',
CurrencyCode:
'USD',
CurrencyName:
'US Dollar',
CurrencySymbol:
'$',
CountryName:
'USA',
CountryISO:
'US',
OpenFigi:
'BBG000G2GJT7',
ISIN:
NULL,
CUSIP:
NULL,
CIK:
'818033',
EmployerIdNumber:
'94-2875566',
FiscalYearEnd:
'December',
IPODate:
'1987-08-26',
InternationalDomestic:
'Domestic',
Sector:
'Healthcare',
Industry:
'Biotechnology',
HomeCategory:
'Domestic',
IsDelisted:
false,
}
Heron Therapeuti Fundamental Data is available in our Financial Data APIs
- Net Revenue 136 M
- EBITDA -26 020 000
- Earnings Per Share -0.25
- Income Statements
- Balance Sheets
- Cash flows
of Fundamental API Data
Get Heron Therapeuti Earnings via APIs
- Latest Release 2024-08-06
- EPS/Forecast -0.04
Get Heron Therapeuti End-of-day Data via APIs
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Get Heron Therapeuti latest news via APIs
Heron (HRTX) Gains 19% on FDA Nod for Zynrelef Label Expansion
Heron Therapeutics, Inc. HRTX announced that the FDA has approved a supplemental new drug application (sNDA), seeking label expansion of Zynrelef (bupivacaine and meloxicam) extended-release solution ...
Do you have any questions?
Our 24/7 support would be happy to assist you via chat or email:
support@eodhistoricaldata.comVisit also:
